Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Epigenetics >  HDAC inhibitors >  Entinostat

Entinostat

Basic information Safety Related Supplier
Entinostat Basic information
Entinostat Chemical Properties
  • Melting point:159-160 ºC
  • Density 1.315
  • storage temp. −20°C
  • solubility DMSO: 38 mg/mL, soluble
  • form solid
  • InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-N
Safety Information
Entinostat Usage And Synthesis
  • DescriptionEntinostat (SNDX-275, MS-275) belongs to benzamide class HDACi and inhibits HDAC1 and 2, 3 and 9 and has low effect against HDAC4, 6, 7 and 8 (Khan et al. 2007). Entinostat is in phase II clinical trial for treatment of Hodgkin's lymphoma and advanced breast cancer (in combination with aromatase inhibitors) and metastatic lung cancer (in combination with erlotinib).
  • Chemical PropertiesYellow Solid
  • UsesEntinostat is an emerging HDACi (histone deacetylase inhibitor). Entinostat is used for treatment of solid tumors and hematologic malignancies.
  • DefinitionChEBI: A member of the class of benzamides resulting from the formal condensation of the carboxy group of the pyridin-3-ylmethyl carbamate derivative of p-(aminomethyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an inhibit r of histone deacetylase isoform 1 (HDAC1) and isoform 3 (HDAC3).
  • Clinical UseEntinostat is an HDAC inhibitor with a relatively long half-life (averaging between 33 and 52 hours). Trials have shown significant biological activity in patients with hematological malignancies receiving entinostat treatments. However, the efficacy of entinostat as a single-agent therapy remains limited. Reported dose-limiting toxicities associated with entinostat include neurotoxicity, fatigue, hypophosphatemia, anorexia, and vomiting.
    The large number of clinical trials using HDAC inhibitors for the treatment of patients with hematological malignancies has demonstrated that these drugs are relatively well tolerated. Although the responses with the currently-available HDAC inhibitors are still limited, there are significant responses in some patients with advanced disease, where options are limited. With better patient selection and the development of more potent HDAC inhibitors, targeting HDACs for the treatment of hematological malignancies remains promising. Furthermore, a growing body of literature suggests that HDAC inhibitors may potentiate some of the currently used cytotoxic or biologic therapies based on their mechanism of action, with multiple trials currently ongoing. Promising combination partners include proteosome inhibitors, DNA demethylating agents, and anthracyclines.
Entinostat(209783-80-2)Related Product Information
EntinostatSupplierMore
  • Company Name:AdooQ Bioscience CHINA Gold
  • Tel:025-58849295
  • Email:info@adooq.cn
  •  
  • Company Name:Shanghai Boyle Chemical Co., Ltd.
  • Tel:
  • Email:sales@boylechem.com
  •  
  • Company Name:J & K SCIENTIFIC LTD.
  • Tel:400-666-7788 010-82848833-
  • Email:jkinfo@jkchemical.com;market6@jkchemical.com
  •  
  • Company Name:Chembest Research Laboratories Limited
  • Tel:021-20908456-
  • Email:sales@BioChemBest.com
  •  
  • Company Name:Chemfun Medical Technology(Shanghai) Co., Ltd.
  • Tel:021-67220633 & 021-37212706
  • Email:chemfun@chemfun.net
  •